Recent publications · Crossref
5 total works indexed
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
· 2017 · cited 1,947x
- Signaling from Rho to the Actin Cytoskeleton Through Protein Kinases ROCK and LIM-kinase
· 1999 · cited 1,344x
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
· 2016 · cited 989x
- Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
· 2022 · cited 731x
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
· 2017 · cited 646x
via Crossref · CC0
Available in 13 languages
via Wikidata sitelinks · CC0